Fourteen well-described caffeine withdrawal symptoms factor into three clusters.
BACKGROUND
Abrupt cessation of caffeine often results in several withdrawal symptoms among habitual caffeine consumers.


OBJECTIVE
The objective of the study was to determine whether caffeine withdrawal symptoms co-exist as clusters in some individuals.


METHODS
Withdrawal symptoms and caffeine intake were assessed for men (n=126) and women (n=369), aged 20-29, using a caffeine habits questionnaire and a semi-quantitative food frequency questionnaire, respectively. Principal components factor analysis was used to identify common underlying factors among 14 well-described caffeine withdrawal symptoms. Odds ratios (OR) and 95% confidence intervals (CI) were calculated to determine if the likelihood of reporting a withdrawal factor was associated with habitual caffeine consumption.


RESULTS
The 14 withdrawal symptoms were grouped into three factors termed "fatigue and headache", "dysphoric mood", and "flu-like somatic". The likelihood of reporting the fatigue and headache and dysphoric mood factors increased with higher levels of habitual caffeine consumption. Compared to <100 mg/day of caffeine, the ORs (95% CI) of reporting the fatigue and headache factor with a habitual intake of 100-200 mg/day and >200 mg/day were 1.97 (1.21, 3.21) and 4.44 (2.50, 7.86), respectively. The corresponding ORs (95% CI) for the dysphoric mood factor were 1.55 (0.96, 2.52) and 3.34 (1.99, 5.60).


CONCLUSIONS
The 14 well-described caffeine withdrawal symptoms factor into three clusters, suggesting the existence of three distinct underlying mechanisms of caffeine withdrawal. Increasing habitual caffeine consumption is associated with an increased likelihood of reporting the fatigue and headache and dysphoric mood symptoms, but not the flu-like somatic symptoms.
Ozsungur
Stephen
S
Department of Nutritional Sciences, Room 350, University of Toronto, 150 College St, Toronto, ON, M5S 3E2, Canada.
Brenner
Darren
D
El-Sohemy
Ahmed
A
D000328:Adult; D002110:Caffeine / Q000008:administration & dosage / Q000009:adverse effects*; D000697:Central Nervous System Stimulants / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D016013:Likelihood Functions; D008297:Male; D016017:Odds Ratio; D025341:Principal Component Analysis; D013375:Substance Withdrawal Syndrome / Q000503:physiopathology*; D011795:Surveys and Questionnaires; D055815:Young Adult
D000697:Central Nervous System Stimulants; D002110:Caffeine
J Pharmacol Exp Ther. 1999 Apr;289(1):285-94
10087016
Lancet. 1990 Sep 8;336(8715):632
1975402
J Pharmacol Exp Ther. 1990 Dec;255(3):1123-32
2262896
Clin Pharmacol Ther. 1969 Jul-Aug;10(4):477-88
5793752
Behav Pharmacol. 1994 Jun;5(3):231-238
11224272
Drug Alcohol Depend. 1998 Oct 1;52(2):99-107
9800139
Arch Gen Psychiatry. 1991 Jul;48(7):611-7
2069491
Psychopharmacology (Berl). 2004 Oct;176(1):1-29
15448977
J Psychopharmacol. 1996 Jan;10(2):110-8
22302887
Curr Opin Lipidol. 2007 Feb;18(1):13-9
17218826
J Pharmacol Exp Ther. 1986 Nov;239(2):416-25
3772801
Food Chem Toxicol. 1996 Jan;34(1):119-29
8603790
Pharmacol Rev. 1999 Mar;51(1):83-133
10049999
Am J Epidemiol. 2001 Dec 15;154(12):1126-35
11744518
Exp Clin Psychopharmacol. 1997 Nov;5(4):393-8
9386966
J Clin Pharmacol. 1999 Dec;39(12):1221-32
10586387
Drug Alcohol Depend. 1993 May;32(3):239-46
8348875
Psychopharmacology (Berl). 1988;94(4):437-51
3131789
Med J Aust. 1981 Feb 7;1(3):146
7219293
Pharmacol Biochem Behav. 1994 Aug;48(4):899-908
7972294
Psychopharmacology (Berl). 2000 Jan;147(4):371-7
10672630
Am J Drug Alcohol Abuse. 2006;32(4):493-502
17127537
N Engl J Med. 1992 Oct 15;327(16):1109-14
1528206
Pharmacol Biochem Behav. 1997 Sep;58(1):203-8
9264092
Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1964 May 25;248:269-78
14230240
Physiol Behav. 1998 Aug;65(1):171-5
9811379
JAMA. 1994 Oct 5;272(13):1043-8
8089887